What Is PT-141?
PT-141, generic name Bremelanotide, was FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works through a mechanism that separates it from drugs like Viagra or Cialis entirely: those drugs target blood flow; PT-141 targets the central nervous system. It is a melanocortin receptor agonist — specifically MC3R and MC4R in the brain — which are involved in regulating sexual arousal, appetite, and energy expenditure.
The Melanocortin System — Why This Mechanism Is Different
Melanocortin receptors are distributed throughout the brain's hypothalamus — a region central to appetite, energy balance, and aspects of libido. By activating these receptors centrally, PT-141 can generate arousal pathways that are independent of genital blood flow. This is precisely why researchers became interested in it for cases where the underlying issue is desire and arousal rather than physical function. The mechanism is genuinely novel in approved sexual health pharmacology.
Clinical Evidence: The RECONNECT Trials
The Phase 3 clinical program enrolled over 1,200 women with diagnosed HSDD. The RECONNECT trials showed statistically significant improvements in both sexual desire and the distress associated with low desire compared to placebo across multiple endpoints. The improvement in satisfying sexual events was approximately 0.7 additional events per month over placebo — modest in absolute terms but consistent and statistically robust. The FDA found this sufficient for approval given HSDD's significant impact on quality of life.
Enjoying this? Get weekly peptide research in your inbox →
FDA Approval, Prescription Access, and Off-Label Use
FDA approval means PT-141/Vyleesi can be legally prescribed by a licensed provider, dispensed by a licensed pharmacy, and used for its indicated condition. Compounding pharmacies can also produce Bremelanotide for off-label applications. This legal clarity puts PT-141 in a categorically different position from research chemicals like BPC-157 — there is an established, legal, medically supervised pathway to access it. Off-label use in men (for erectile dysfunction) exists in clinical practice, but this indication is not FDA-approved.
Side Effects: What the Trials Documented
The most significant side effect in trials was nausea — reported by 40% of participants, which is high enough to appear prominently in the FDA label. The prescribing recommendation is to take PT-141 at least 45 minutes before sexual activity and no more than once in 24 hours. Blood pressure increases were also documented — the drug carries a specific warning about transient BP elevation, which matters for anyone with cardiovascular considerations. These are not trivial side effects and represent important context for any research evaluation.